AzTrials
AzTrials

TaurineTauAgeNCT06613542

Effects Of Daily Taurine Intake For 6 Months On Biological Age and Body Metabolism Indicators As Well As Physical Fitness In 55-75-year-old Women And Men

A study testing 4g of taurine daily in people with Taurine and Aging, Biological, run by Technical University of Munich at 1 site in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to investigate the effect of taking 4 grams of taurine by older adults on aging processes over a period of 6 months. It will also check for effects of taurine on participant's physical fitness, metabolic and cognitive functions. Read more about this study

Who is it for?
Ages 55 to 75 yearsHealthy volunteers can take part
Conditions the study is for
Taurine, Aging, Biological, Physical Activity
What is being tested?
4g of taurine daily
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
90 participants
Where
1 siteGermany
Study dates
25 Sep 2024to 13 Nov 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • women or men
  • Age 55 - 75
  • BMI 22 - 30 kg/m²
  • written consent

Who cannot join

  • Acute or chronic inflammation (e.g. flu infection)
  • Severe chronic illness (e.g., Type 1 or Type 2 diabetes mellitus, COPD, renal insufficiency)
  • Myocardial infarction or stroke in the previous 6 months
  • Psychiatric disorder, including depression or dementia
  • Weight change of ≥ 5 kg in the last 6 months

Trial locations and contacts

1 site in 1 country.

Germany1 site

  • Institute for Nutritional Medicine of Technical University of Munich

    Munich, 80992

Other trials in Germany

About this study

Official title: Effect Of Daily Taurine Supplementation For 6 Months On Biological Age and Metabolic Biomarkers As Well As Physical Fitness In 55-75-year-old Women And Men: A Randomized Controlled Intervention Study

The goal of this clinical trial is to investigate the effect of taking 4 grams of taurine by older adults on aging processes over a period of 6 months. It will also check for effects of taurine on participant's physical fitness, metabolic and cognitive functions. The main question it aims to answer is:

  • Does a supplementation with 4 g of taurine daily over a period of 6 months slow down biological aging in humans? Researchers will compare supplementation with taurine to a placebo (a look-alike substance that contains no drug) to reliably determine whether taurine has an effect.
Read more

Participants will:

  • Take 4g of taurine or a placebo every day for 6 months
  • Visit the study site 4 times for checkups and tests: for a screening visit, at the beginning of the intervention, after 8 and 24 weeks
Read the detailed description

Measurements performed during study visits:

  • Biological age estimate via proteome analysis
  • Organ age estimates (proteomics)
  • DNA methylation
  • Inflammatory biomarkers (CRP, cytokines)
  • Metabolic variables: fasting blood glucose, insulin, HOMA-IR, HbA1c, lipids, BMI
  • Physical fitness (hand grip strength, leg extensor strength, PWC130)
  • Resting energy expenditure
  • Cognitive function via questionnaire
  • Quality of life
  • Heart rate variability
  • Physical activity, nutrition
Being tested
4g of taurine daily, Placebo
Keywords
taurine, biological aging, metabolic health, anti-aging, epigenetic clock, aging, physical activity, cognition, Cellular Senescence, hallmarks of aging, humans, Dietary Supplements, longevity, Taurine Deficiency, Taurine Level, aging metabolism, longevity physiology, drug effects, DNA-methylation, aging ptoeomics
Medical subject headings
Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 4g of taurine dailyDietary supplement

    Intervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months

  • PlaceboDietary supplement

    Controll group (4g of placebo/day): 2g of placebo (4 capsules, 500mg each) in the morning and 2g of placebo (4 capsules, 500mg each) in the evening for 6 months

Study groups in NCT06613542
Study groupRoleWhat they receive
4g of taurine dailyActive comparatorIntervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months
Receives: Dietary Supplement: 4g of taurine daily
PlaceboPlacebo comparatorNot described
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Biological Age At 6 Months (Proteome Analysis)

    The primary objective of the study is to answer the following research question:

    Does a 6-month supplementation with 4g of taurine daily slow down biological aging in humans?

    Biological age will be determined using a plasma proteome analysis and established machine learning models based on plasma and urine samples. This will also include an analysis of organ-specific aging.

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  2. Change From Baseline in Biological Age At 6 Months (DNA Methylation)

    The primary objective of the study is to answer the following research question:

    Does a 6-month supplementation with 4g of taurine daily slow down biological aging in humans?

    Biological age will be estimated by assessing DNA methylation patterns (epigenetic clock) from plasma, urine, and oral mucosa samples.

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

Secondary outcomes (12)

  1. Change From Baseline In Cognitive Functions at 6 Months

    Does a 6-month supplementation with 4 g of taurine daily influence parameters of mental health?

    Methods of measurement: MoCA (Montreal Cognitive Assessment)

    Measured: pre-intervention (at time point 0) and post-intervention (after 24 weeks)

  2. Change From Baseline In Cardiometabolic Risk Profile at 6 Months

    Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?

    Measurement: fasting blood glucose in mg/dL

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  3. Change From Baseline In Cardiometabolic Risk Profile at 6 Months

    Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?

    Measurement: Body-Mass-Index determined by participants weight in kilograms divided by height in metres squared.

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  4. Change From Baseline In Cardiometabolic Risk Profile at 6 Months

    Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?

    Measurement: blood pressure in mmHg

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  5. Change From Baseline In Cardiometabolic Risk Profile at 6 Months

    Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?

    Measurement: total cholesterol in mg/dl

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  6. Change From Baseline In Cardiometabolic Risk Profile at 6 Months

    Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?

    Measurement: LDL-cholesterol in mg/dL

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  7. Change From Baseline In Cardiometabolic Risk Profile at 6 Months

    Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?

    Measurement: HDL-cholesterol in mg/dL

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  8. Change From Baseline In Cardiometabolic Risk Profile at 6 Months

    Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?

    Measurement: C-reactive protein in mg/l

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  9. Change From Baseline In Cardiometabolic Risk Profile at 6 Months

    Does a 6-month supplementation with 4 g of taurine daily alter the cardiometabolic risk profile?

    Measurement: fasting insulin in pmol/l

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  10. Change From Baseline In Handgrip Strength (kg) at 6 Months

    Measurement of handgrip strength in kilograms and Newtons in the dominant hand using Jamar Hydraulic Hand Dynamometer.

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  11. Change From Baseline In Physical Working Capacity (PWC130) At 6 Months

    Measurement of heart rate (bpm) on the Corvial ergometer while increasing power manually by 25 W every 2 minutes. The endpoint is the power in Watts at the stage where heart rate of 130bpm is reached.

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

  12. Change From Baseline In Isometric Leg Extensor Strength For Each Leg At 6 Months

    Measurement of leg extensor strength using a force transducer connected to the back of a chair and an ankle loop, as well as force recording software. The maximum force (N) will be multiplied with the distance from knee joint to the middle of the loop (in metres) to calculate the torque in Newton-metres (Nm) for each leg.

    Measured: pre-intervention (at time point 0) and post-intervention (at 24 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Sep 2024
  2. Study start25 Sep 2024
  3. Primary completion13 Nov 2025
  4. Study completion13 Nov 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06613542
Sponsor's protocol ID
2024-253-S-CB
Acronym
TauAge
Status last verified
Nov 2025
First submitted
17 Sep 2024
Last updated
21 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: IPD will not be shared because of data privacy and confidentiality.

Publications

  • Oh HS, Rutledge J, Nachun D, Palovics R, Abiose O, Moran-Losada P, Channappa D, Urey DY, Kim K, Sung YJ, Wang L, Timsina J, Western D, Liu M, Kohlfeld P, Budde J, Wilson EN, Guen Y, Maurer TM, Haney M, Yang AC, He Z, Greicius MD, Andreasson KI, Sathyan S, Weiss EF, Milman S, Barzilai N, Cruchaga C, Wagner AD, Mormino E, Lehallier B, Henderson VW, Longo FM, Montgomery SB, Wyss-Coray T. Organ aging signatures in the plasma proteome track health and disease. Nature. 2023 Dec;624(7990):164-172. doi: 10.1038/s41586-023-06802-1. Epub 2023 Dec 6.

    PubMed 38057571

  • Singh P, Gollapalli K, Mangiola S, Schranner D, Yusuf MA, Chamoli M, Shi SL, Lopes Bastos B, Nair T, Riermeier A, Vayndorf EM, Wu JZ, Nilakhe A, Nguyen CQ, Muir M, Kiflezghi MG, Foulger A, Junker A, Devine J, Sharan K, Chinta SJ, Rajput S, Rane A, Baumert P, Schonfelder M, Iavarone F, di Lorenzo G, Kumari S, Gupta A, Sarkar R, Khyriem C, Chawla AS, Sharma A, Sarper N, Chattopadhyay N, Biswal BK, Settembre C, Nagarajan P, Targoff KL, Picard M, Gupta S, Velagapudi V, Papenfuss AT, Kaya A, Ferreira MG, Kennedy BK, Andersen JK, Lithgow GJ, Ali AM, Mukhopadhyay A, Palotie A, Kastenmuller G, Kaeberlein M, Wackerhage H, Pal B, Yadav VK. Taurine deficiency as a driver of aging. Science. 2023 Jun 9;380(6649):eabn9257. doi: 10.1126/science.abn9257. Epub 2023 Jun 9.

    PubMed 37289866

Questions about this trial

What is this clinical trial studying?

A study testing 4g of taurine daily in people with Taurine and Aging, Biological, run by Technical University of Munich at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Biological Age At 6 Months (Proteome Analysis) (time frame: pre-intervention (at time point 0) and post-intervention (at 24 weeks)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06613542, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in